Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Black Diamond Therapeutics (Nasdaq:BDTX) announced that CEO Mark Velleca, M.D., Ph.D., will join a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026, from 4:55–5:25 p.m. ET.

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq:BDTX) announced that CEO Mark Velleca, M.D., Ph.D., will join a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026, from 4:55–5:25 p.m. ET. A live and archived webcast will be available.

Argus May 22 session

-35.77% close to close 5.6x rel. volume Open Argus

Details

News Market Reaction – BDTX

On May 22, the day this news came out, BDTX closed 35.77% below the previous close. That session’s volume was 5.6x the stock’s average daily volume.

Data tracked by StockTitan Argus for the May 22 session.

Key Figures

Conference date: June 3, 2026 Presentation time: 4:55-5:25pm ET Webcast archive duration: 90 days

Conference date

June 3, 2026

Jefferies Global Healthcare Conference fireside chat

Presentation time

4:55-5:25pm ET

Scheduled window for Jefferies fireside chat

Webcast archive duration

90 days

Replay availability following the Jefferies event

Historical Context

5 past events · Latest: May 19

5 events

1. May 19

   Clinical webcast update

   24h Move

   +16.3%

   Announced investor webcast to review updated Phase 2 silevertinib data.

2. May 07

   Quarterly earnings update

   24h Move

   -3.5%

   Reported Q1 2026 financials and reiterated cash runway and clinical progress.

3. Apr 21

   ASCO presentation notice

   24h Move

   +3.3%

   Outlined multiple ASCO 2026 presentations of Phase 2 silevertinib data.

4. Mar 16

   Full-year results, pipeline

   24h Move

   +1.8%

   Reported 2025 turnaround, strong cash, and encouraging Phase 2 silevertinib metrics.

5. Mar 02

   Investor conferences

   24h Move

   -5.3%

   Notified investors of multiple upcoming conference presentations and meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

oncology, oncogenic mutations, webcast

3 terms

oncology medical

"Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing..."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

oncogenic mutations medical

"developing MasterKey therapies that target families of oncogenic mutations in patients..."

Oncogenic mutations are changes in a cell's DNA that push the cell to grow and divide uncontrollably, transforming a normal cell toward cancer. They matter to investors because pinpointing which mutations cause disease guides the creation of targeted drugs, diagnostics and tests — similar to finding the exact broken part in a machine so a company can build a precise repair with clear market and regulatory value.

webcast technical

"The Webcast will be available at the start of the presentation under “Events and Presentations”..."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

• 4:55-5:25pm ET on Wednesday, June 3
  
  

The Webcast will be available at the start of the presentation under “Events and Presentations” on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Black Diamond Therapeutics (BDTX) present at the Jefferies Global Healthcare Conference 2026?

Black Diamond Therapeutics will present at the Jefferies Global Healthcare Conference on June 3, 2026, from 4:55–5:25 p.m. ET. According to the company, this session will feature a fireside chat with CEO Mark Velleca in New York.

Who will represent Black Diamond Therapeutics (BDTX) at the Jefferies Global Healthcare Conference fireside chat?

Black Diamond Therapeutics will be represented by its Chief Executive Officer, Mark Velleca, M.D., Ph.D., in the fireside chat. According to the company, he will discuss the business on June 3, 2026, at the Jefferies Global Healthcare Conference in New York.

How can investors watch the Black Diamond Therapeutics (BDTX) Jefferies conference webcast?

Investors can watch the live webcast under “Events and Presentations” in the Investors section of Black Diamond Therapeutics’ website. According to the company, the webcast will start at the presentation time and be accessible online without listed geographic restrictions.

Will a replay of Black Diamond Therapeutics’ (BDTX) Jefferies Global Healthcare Conference presentation be available?

Yes, a replay of the webcast will be available and archived for 90 days following the event. According to the company, investors can access this replay in the Investors section of its website under the “Events and Presentations” page.

Is Black Diamond Therapeutics (BDTX) hosting one-on-one investor meetings at the Jefferies Global Healthcare Conference?

Yes, Black Diamond Therapeutics will host one-on-one meetings with investors on June 3, 2026, alongside its fireside chat. According to the company, these meetings will occur the same day as the scheduled conference presentation in New York.

Where is the Jefferies Global Healthcare Conference session for Black Diamond Therapeutics (BDTX) being held?

The Black Diamond Therapeutics session at the Jefferies Global Healthcare Conference will take place in New York, NY, on June 3, 2026. According to the company, the presentation is scheduled from 4:55–5:25 p.m. ET with an accompanying webcast.